We have observed
16 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after February 18, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
THERAPEUTIC AGENTS WITH IMPROVED FIBRINOGEN BINDING
Use of Recombinant LAG-3 or the Derivatives Thereof for Eliciting Monocyte Immune Response
ZEOLITIC CATALYTIC CONVERSION OF ALCOHOLS TO HYDROCARBONS
Soluble analyte detection and amplification
ACTIVE MATERIALS FOR PREVENTION AND TREATMENT OF FOULED SURFACES
METHODS FOR OBTAINING LIQUID FROM A SOLID PHASE
HYDROTHERMALLY STABLE, LOW-TEMPERATURE NOX REDUCTION NH3-SCR CATALYST
ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
CATALYTIC CONVERSION OF ALCOHOLS TO HYDROCARBONS WITH LOW BENZENE CONTENT
HIV VIRAL LOAD TESTING
COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER
COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER OR INFECTION
ADENO-ASSOCIATED VIRUS VARIANTS AND METHODS OF USE THEREOF